Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2014

View Archived Issues

Mezzion Pharma begins evaluation of udenafil in adolescents with single ventricle heart defects

First patient treated in phase I study of MVA-BN Brachyury in advanced cancer

Sumitomo Dainippon to invest in Remiges BioPharma Fund

Essentialis secures grant to advance DCCR in Prader-Willi syndrome

Novel agents for HIV infection patented by Gilead Sciences

Rich Pharmaceuticals hires CRO for help on lead compound RP-323

BioFire Diagnostics begins study of FilmArray Meningitis/Encephalitis Panel

Merck KGaA commits to Chinese growth market

Patrys updates on preclinical pipeline progress

Bristol-Myers Squibb and Ono form strategic anticancer alliance in Japan, South Korea and Taiwan

Gilead Sciences signs new agreement with Medicines Patent Pool for tenofovir alafenamide

World Hepatitis Day: Advances in combination treatments and immunotherapies for chronic disease

Novel PI3Kdelta and gamma inhibitors disclosed by Aurigene Discovery Technologies

FDA clears IND for phase I study of MGD-007 for colorectal cancer

Topline results from phase III trial of sorafenib plus capecitabine in advanced breast cancer

Bristol-Myers Squibb reveals highlights of second quarter 2014

Results presented on MVTT-based HIV vaccine development

Gilead Sciences designs new anti-HIV agents

Kalvista Pharmaceuticals discloses new plasma kallikrein inhibitors

Xellia Pharmaceutical patents novel polymyxin antibiotics

Phase II results presented for TB vaccine in HIV-infected adults

Assembly decides against further development of VEN-307

CHMP adopts positive opinion for Imbruvica in CLL and MCL

EMA committee recommends approval of Zydelig in CLL and follicular lymphoma

CHMP recommends extension of Ozurdex indication in diabetic macular edema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...